Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2026/03/26 02:48 EDT
Regular Hours
Last
 84.62
+2.03 (+2.46%)
Day High 
84.85 
Prev. Close
82.59 
1-M High
103.25 
Volume 
1.15M 
Bid
72.11
Ask
85.1
Day Low
80.99 
Open
82.6 
1-M Low
80.7 
Market Cap 
5.64B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 87.76 
20-SMA 90.7 
50-SMA 98.39 
52-W High 122.2 
52-W Low 45.905 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.11/-0.26
Enterprise Value
5.64B
Balance Sheet
Book Value Per Share
2.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
189.76M
Operating Revenue Per Share
0.64
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TERNTerns Pharmaceuticals52.86+2.86+5.72%-- 
ADMAADMA Biologics9.63-1.7-15.00%19.2PE
QNCXQuince Therapeutics0.102+0.0089+9.56%-- 
IBRXImmunityBio8.07+0.655+8.83%-- 
SRPTSarepta Therapeutics23.77+6.16+34.98%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.